Pfizer
NEWS
Pfizer and BioNTech announced that their COVID-19 vaccine was probably just as effective against the variant strain of the virus, B.1.1.7, found in the U.K.
Will there be enough doses of the two authorized mRNA COVID-19 vaccines to meet the lofty goal of 100 million inoculations within 100 days of the start of Joe Biden’s presidential administration?
The U.S. FDA approved Pfizer’s Xalkori (crizotinib) for pediatric patients one year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase (ALK)-positive.
Pfizer anticipates the initiative to invest up to half-a-billion dollars in small- to medium-sized companies developing clinical-stage assets aligned with Pfizer’s core areas of focus.
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Here’s a run-down of some of the most recent collaboration announcements this week.
Pfizer is giving itself a corporate facelift, dropping its traditional blue-pill company logo in favor of a double helix DNA spiral that reflects the advances in medical science that have placed the curing of multiple diseases within reach.
JOBS
IN THE PRESS